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SI Materials and Methods
Computational Methodology. We manually aligned the C-C che-
mokine receptor type 5 (CCR5) transmembrane (TM) sequence
to the sequences of four available G protein-coupled receptors
(GPCRs): bovine rhodopsin (PDB ID code 1u19), human β2
adrenergic receptor (PDB ID code 2rh1), human adenosine A2A
receptor (PDB ID code 3eml), and turkey β1 adrenergic receptor
(PDB ID code 2vt4) using the conserved residues found in each
TM. We predicted the lengths of the CCR5 TMs based on the
PredicTM approach that predicts the hydrophobic helical re-
gions and combines them with the output of three prediction
servers—Porter (1), APSSP2 (2) and PsiPred (3)—to predict any
helical extensions beyond the membrane. The starting structure
of the TM bundle for each template was obtained by mutating
the template residues to the CCR5 residues (as in homology
modeling) but using the SideChain Rotamer Energy Analysis
Method (SCREAM) side-chain optimization protocol and a 100-
step minimization of TMs (with the Dreiding force field) per-
formed independently for each helix (i.e., without the presence
of other helices) (4, 5). Afterward, the mutated and optimized
helices were put back together to form a seven-helix bundle. This
approach yielded four CCR5 seven-transmembrane helical do-
mains, each based on a different experimental GPCR structure.
In the next step, the BiHelix step (6) was performed, followed by
the SuperBiHelix step (7), as described in Prediction of the CCR5
Structure in the main text.
Because some loop residues (e.g., K191) were suggested to be
important for ligand binding, we modeled the extracellular loops
of CCR5 before ligand docking, Thus, we built the extracellular
loops and N terminus using homology approaches and the se-
quence similarity to human β2 adrenergic receptor loops (ex-
tracellular loop 1, 12 first residues of the extracellular loop 2)
and human adenosine A2A receptor loops (last 14 residues of
the extracellular loop 2, extracellular loop 3). We built the N
terminus using the part of the bovine rhodopsin N terminus
fused with the experimental NMR structure of the middle part of
the CCR5 N terminus (PDB ID code 2RLL). After mutating the
residues to the respective CCR5 residues using the SCREAM
protocol, the loops were connected to the proper helices, and the
connected regions were minimized for 1,000 steps using a Dreiding
force field.
The intracellular loops and helix 8 were modeled after docking,
using an approach similar to that used for the extracellular loops,
with homology modeling and sequence similarity to human β2
adrenergic receptor loops.
Before the docking of each CCR5 ligand described in this work
[Maraviroc (MVC), PF-232798 (PF), Aplaviroc (APL), and TAK-
779 (TAK)], we carried out a search over conformational space.
Here, torsionally diverse conformations for each ligand were gen-
erated by the Maestro MacroModel program using a 0–10 kcal/mol
window and requesting 10,000 poses. These conformations were
clustered at 2.0 Å heavy-atom rmsd into a number of diverse
families whose family heads were then docked to the selected
CCR5 models. This procedure yielded 17 different conformations
for Aplaviroc, 31 conformations for Maraviroc, 35 conformations
for PF-232798, and 22 conformations for TAK-779. Each of these
conformations was docked to each of the ∼10 ensembles of protein
conformations using the DarwinDock protocol.
The DarwinDock protocol used in this study relied on sampling
a complete set of ligand poses (∼50,000) in the potential binding
regions for each ligand conformation. In the first step, each of the
CCR5 model binding sites had the bulky, hydrophobic residues
(ILE, LEU, PHE, TRP, TYR, and VAL) mutated to alanine
residues to allow flexibility in the binding site. Next, ∼300 poses
were selected for each CCR5 model–ligand pair using the lowest-
energy criterion a Dreiding force field and three different scoring
criteria: total energy, polar energy (defined as the sum of cou-
lombic and H-bonding energy contributions to the total energy),
and hydrophobic energy (defined as Van der Waals energy con-
tribution to the total energy). Afterward, the bulky hydrophobic
residues were restored to the original ones, and the entire binding
had the side chains optimized using the SCREAM protocol. This
approach allows a different side-chain conformation for each of
the 300 poses. In the next step, a 10-step optimization of the
binding site was performed using a Dreiding force field from
which we selected 50% of the lowest-energy poses for further
refinement. The computational charge neutralization of the whole
system was then performed by mutating the charged residues of
the CCR5 (ASP, ARG, GLU, and LYS) to their charge-neutral
forms as well as detaching the most basic hydrogen atom from
Aplaviroc, Maraviroc, or PF-232798 to change the formal charge
of these ligands from +1 to 0. These neutral protein-ligand sys-
tems were subjected to a 10-step minimization run, and half of
the lowest-energy poses were selected for the final step. Here,
a 100-step minimization of the entire ligand–protein complex
was performed and the best systems were selected based on the
lowest total energy of the neutral system.
The procedure of obtaining models of CCR5 mutants was the
following for each mutation listed in Table 1. For each of the top
100 CCR5 models obtained in the SuperBihelix step, the specific
residue was mutated, the respective side chain was optimized using
the SCREAM protocol, and the entire protein was minimized for
100 steps. Then, the CCR5 mutant models were rescored using an
average of total and interhelical energies with the Dreiding force
field. This procedure allowed for the evaluation of the structural
changes in the apo form of the protein upon mutations.
The top 10 mutant receptor structures were selected and used
for ligand docking. In this step, a simpler docking protocol was
used, in which, for each ligand, the final pose from theDarwinDock
step was taken and its coordinates were matched to each of the 10
low-energy CCR5 model mutants, followed by a binding-site op-
timization. The complexes were evaluated, and one ligand–mutant
complex with the lowest total energy was selected. This procedure
allowed the ligand to “choose” a different conformation for each
CCR5 mutation studied.
Experimental Generation of CCR5 Mutants. Experimental mutations
in the ORF of the human CCR5 gene were carried out using
the quick change lightning site-directed mutagenesis kit (Agilent
Technologies) following the kit’s recommendations. Briefly, forward
and reverse DNA primers (10 pmol each) encompassing the amino
acid to be mutated were mixed with kit components and 40 ng of
the mammalian expression vector pcDNA6.2 /V5/GW/D-Topo
(Invitrogen) containing the human CCR5 ORF as a template.
After 18 rounds of PCR amplification, the template in the re-
action was digested with the DpnI restriction enzyme for 30 min at
37 °C, and then 2 μL was transformed into XL-10 gold ultra-
competent bacteria (Agilent Technologies) following the kit’s in-
structions. Bacteria from the transformation reaction was plated
into LB-Ampicillin agar plates at three different densities and
incubated overnight at 37 °C. Next day, for each CCR5 mutation
made, five bacterial colonies were picked and grown in LB media
overnight. From these cultures, plasmid mini preps were performed
using QIAprep spin miniprep kit (Qiagen), and the specific
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mutations within the CCR5 gene were verified by sequencing the
complete ORF using specific primers.
Once bacterial clones containing sequence-verified CCR5
mutants were obtained, endotoxin-free plasmid maxiprep was
done (Qiagen) to obtain specific mutant CCR5 expression vec-
tors. These vectors were later used in Maraviroc ligand-binding
assays for structure–activity relationship (SAR) studies.
Ligand-Binding Experiments.Tritium-labeledMaraviroc (99 Ci/mmol)
was custom-made at Amersham-GE Healthcare Life Sciences. To
prepare membranes for ligand-binding studies, CCR5 expression
constructs were transiently transfected into HEK-293 cells (ATCC
no. CRL-1573) using the Effectene Transfection Reagent (Qiagen)
according to the manufacturer’s instructions. The cells were har-
vested 3 d posttransfection as follows. Transfected cells grown on
T-225 flasks (two flasks per expression construct), rinsed with PBS
containing 5 mM EGTA (PBS/EGTA), and incubated in PBS/
EGTA for 30 min at room temperature. Detached cells were
pelleted at 300 × g for 10 min and resuspended in 8 mL of ice-cold
20 mM Hepes (pH 7.3) containing 1% (wt/vol) protease inhibitors
mixture (Halt; Thermo Fisher). After 10 min on ice, the cells
were homogenized by sonication (7× 20-s bursts). Homogenates
were centrifuged at 300 × g for 10 min, and supernatants were
collected and centrifuged for 2 h at 50,000 × g. Membranes were
resuspended in 1 mL of 20 mMHepes (pH 7.3) and stored at−70 °C.
Protein content was determined using the BCA Protein Assay Re-
agent (Thermo Fisher).
For receptor-binding studies, 10 μg of membranes were in-
cubated in 96-well polypropylene plates with tritium-labeled
Maraviroc for 2 h at room temperature in 300 μL of binding buffer
containing 50 mM Hepes (pH 7.3), 1 mM CaCl2, 5 mM MgCl2,
0.1% DMSO, and 0.5% BSA. Nonspecific binding was measured
in the presence of 1,000-fold excess of unlabeled Maraviroc. The
samples were filtered through UniFilter-96 GF/C plates pre-
blocked with 0.3% polyethylene imine using a Unifilter-96 Har-
vester (PerkinElmer). The filters were washed four times with PBS,
and radioactivity was measured using a TopCount instrument
(PerkinElmer) in 40 μL of MicroScint 20 liquid scintillant. Kd and
Ki values were obtained from saturation and competition binding
experiments, respectively, and calculated using GraphPad Prism
(GraphPad Softaware).
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Scheme S1. Structures of Maraviroc, PF-232798, Aplaviroc, and TAK-779.
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Fig. S1. Schematic representation of the CCR5 residues in the MVC binding site for (A) WT7 (MVC binding CCR5 conformation) with MVC, (B) X-ray CCR5
conformation with MVC, (C) WT7 (PF-232798 binding CCR5 conformation) with PF, and (D) WT1 (lowest energy ranked CCR5 apo WT conformation) no ligand.
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Fig. S2. Structural basis for the effect of the W86A mutation on the wt30 conformation and for the A90H mutation on the wt1 conformation.
Fig. S3. Comparison of predicted effect of PF binding to mutants vs. experimental data. The ±1 kcal/mol lines are shown in green.
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Fig. S4. Comparison of predicted effect of Aplaviroc binding to mutants vs. experimental data. The ±1 kcal/mol lines are shown in green.
Fig. S5. Comparison of predicted effect of Tak-779 binding to mutants vs. experimental data. The ±1 kcal/mol lines are shown in green.
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Table S2. Reordering of CCR5 conformations for W86A, A90H,
and T105A mutants
W86A Avg rank A90H Avg rank T105A Avg rank
wt1 8.0 wt3 3.0 wt1 4.0
wt3 11.8 wt2 6.0 wt3 7.8
wt2 15.0 wt4 15.3 wt2 10.0
wt30 16.0 wt5 16.3 wt11 28.3
wt6 20.8 wt13 18.5 wt9 28.8
wt17 26.0 wt10 21.0 wt12 29.3
wt7 28.3 wt9 22.5 wt18 30.5
wt8 29.3 wt27 22.8 wt4 30.5
wt4 30.0 wt14 23.8 wt27 30.8
wt18 30.3 wt32 24.8 wt6 31.0
wt11 30.3 wt64 25.0 wt7 31.3
wt48 31.0 wt15 25.0 wt20 31.5
wt20 31.3 wt16 25.8 wt8 31.8
wt12 31.3 wt26 27.0 wt14 31.8
wt19 34.8 wt28 27.5 wt13 34.0
wt14 34.8 wt31 28.5 wt15 36.0
wt9 35.8 wt17 29.3 wt5 36.0
wt27 36.0 wt33 30.3 wt64 37.3
wt34 37.0 wt11 32.0 wt32 38.0
wt13 38.0 wt74 32.5 wt30 42.5
Abrol et al. www.pnas.org/cgi/content/short/1413216111 7 of 7
